Have a feature idea you'd love to see implemented?
Let us know!
WGS GeneDx Holdings Corp
Price (delayed)
$72.005
Market cap
$1.98B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.11
Enterprise value
$2.04B
Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic
Highlights
WGS's gross margin has surged by 186% year-on-year and by 6% since the previous quarter
GeneDx Holdings's EPS has surged by 91% YoY and by 30% QoQ
The company's equity fell by 20% YoY but it rose by 5% QoQ
WGS's quick ratio is down by 7% year-on-year but it is up by 2.6% since the previous quarter
WGS's debt has surged by 58% year-on-year
Key stats
What are the main financial stats of WGS
Market
Valuations
Earnings
Shares outstanding
27.47M
Market cap
$1.98B
Enterprise value
$2.04B
Price to earnings (P/E)
N/A
Price to book (P/B)
9.48
Price to sales (P/S)
7.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.62
Revenue
$267.23M
Gross profit
$158.95M
Net income
-$83.5M
EBIT
-$80.92M
EBITDA
-$59.11M
Free cash flow
-$59.84M
Per share
Balance sheet
Liquidity
EPS
-$3.11
EPS diluted
-$3.11
Free cash flow per share
-$2.21
Book value per share
$7.59
Revenue per share
$9.86
TBVPS
$9.11
Total assets
$408.84M
Total liabilities
$204.34M
Debt
$116.1M
Equity
$204.5M
Working capital
$108.67M
Debt to equity
0.57
Current ratio
2.41
Quick ratio
2
Net debt/EBITDA
-0.98
Margins
Efficiency
Dividend
EBITDA margin
-22.1%
Gross margin
59.5%
Net margin
-31.2%
Operating margin
-21.6%
Return on assets
-20.7%
Return on equity
-40.1%
Return on invested capital
-37.6%
Return on capital employed
-24.4%
Return on sales
-30.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
WGS stock price
How has the GeneDx Holdings stock price performed over time
Intraday
-15.3%
1 week
-25.8%
1 month
-4.54%
1 year
1,867.35%
YTD
-6.32%
QTD
-6.32%
Financial performance
How have GeneDx Holdings's revenue and profit performed over time
Revenue
$267.23M
Gross profit
$158.95M
Operating income
-$57.66M
Net income
-$83.5M
Gross margin
59.5%
Net margin
-31.2%
WGS's gross margin has surged by 186% year-on-year and by 6% since the previous quarter
The operating margin has soared by 91% YoY and by 43% from the previous quarter
The operating income has soared by 88% YoY and by 38% from the previous quarter
WGS's net margin has surged by 86% year-on-year and by 35% since the previous quarter
Growth
What is GeneDx Holdings's growth rate over time
Valuation
What is GeneDx Holdings stock price valuation
P/E
N/A
P/B
9.48
P/S
7.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.62
GeneDx Holdings's EPS has surged by 91% YoY and by 30% QoQ
The company's equity fell by 20% YoY but it rose by 5% QoQ
WGS's revenue is up by 29% year-on-year and by 10% since the previous quarter
Efficiency
How efficient is GeneDx Holdings business performance
The ROIC has soared by 90% YoY and by 36% from the previous quarter
GeneDx Holdings's return on sales has surged by 86% YoY and by 37% QoQ
The ROA has soared by 78% year-on-year and by 29% since the previous quarter
The ROE has soared by 75% YoY and by 25% from the previous quarter
Dividends
What is WGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for WGS.
Financial health
How did GeneDx Holdings financials performed over time
WGS's total assets is 100% greater than its total liabilities
The total liabilities has grown by 25% YoY and by 4.8% from the previous quarter
WGS's quick ratio is down by 7% year-on-year but it is up by 2.6% since the previous quarter
WGS's debt is 43% smaller than its equity
The debt to equity has surged by 97% year-on-year but it has declined by 5% since the previous quarter
WGS's debt has surged by 58% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.